Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results

Puma Biotechnology (NASDAQ:PBYI) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06, FiscalAI reports. The firm had revenue of $55.10 million for the quarter, compared to analyst estimates of $57.50 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%.

Here are the key takeaways from Puma Biotechnology’s conference call:

• Q3 revenue was $55.1 million, with net product revenue of $54.1 million, up from $53.6 million in Q2. However, U.S. NERLYNX net sales fell to $50.6 million from $53.6 million, while $3.6 million of product-supply revenue came from international partners.
• NERLYNX demand was mixed: U.S. demand rose 5% year over year but fell 3% quarter over quarter, while new patient starts declined 9% year over year and 13% sequentially. The company also lowered its 2026 product-revenue outlook slightly and cut its royalty forecast to $18–$19 million from $20–$23 million, citing a China royalty-rate reduction after generic market share crossed a threshold.
• Puma raised its full-year 2026 net-income outlook to $20–$22 million from $17–$20 million and expects $10–$12 million in Q4 net income. It ended Q3 with $108.5 million in cash, cash equivalents, and marketable securities and is now debt-free.
• Puma said preliminary ALISCA-Breast1 data supports considering a Phase III alisertib trial; updated interim results are expected at the San Antonio Breast Cancer Symposium in December, with discussions with regulators planned for the first half of 2027. The company also expects additional ALISCA-Lung1 interim data and initial ALISCA-Lung2 data in 2027, though these remain investigational programs.

Puma Biotechnology Trading Down 15.6%

Shares of PBYI stock traded down $1.52 on Friday, hitting $8.25. 1,279,729 shares of the stock were exchanged, compared to its average volume of 359,117. The firm has a market capitalization of $425.87 million, a P/E ratio of 17.94 and a beta of 1.40. Puma Biotechnology has a fifty-two week low of $4.57 and a fifty-two week high of $11.50. The business has a 50-day moving average of $9.88 and a 200 day moving average of $7.99.

Insider Buying and Selling

In other Puma Biotechnology news, Director Troy Wilson sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $9.10, for a total transaction of $45,500.00. Following the completion of the transaction, the director owned 54,750 shares of the company’s stock, valued at $498,225. This represents a 8.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandra Cesano sold 62,150 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $9.12, for a total value of $566,808.00. Following the transaction, the director directly owned 56,700 shares of the company’s stock, valued at approximately $517,104. This trade represents a 52.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 22.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

PBYI has been the subject of several research reports. TD Cowen increased their price objective on shares of Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings raised shares of Puma Biotechnology from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Puma Biotechnology currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.